R Tal-Singer Lung Health Researcher & Advocate 🫁

Both 10mg and 25mg brensocatib has been approved in the US for treatment of bronchiectasis. In the absence of official guidance, Chuck Daley and i comment on optimal dosing, concluding that 25mg should be the preferred dose for patients @ATSBlueEditor academic.oup.com/ajrccm/advance…

Call for Abstracts for Early Career Researchers: share your work at ICAN 2026 (5 September, Barcelona). Join a collaborative community advancing respiratory research — from immune mechanisms and treatment response to AI, imaging, and novel therapies. Connect with peers and global experts across academia, industry, NIH, ERS, and more. Only 50 abstracts will be selected. ✈️ Selected abstracts will receive travel support + accommodation 📅 Deadline: 15 April, 2026 🔗 ican.gaapp.org

Congratulations to @gaapporg #CERT Governance Board members, patient advocates and GSK collaborators on our publication describing the translation, linguistic, and cross-cultural validation of the #COPD Exacerbation Recognition Tool. doi.org/10.15326/jcopd…

Check our new interactive learning module on bronchiectasis - talking about the new ERS guidelines and much more with Sanjay Chotirmall and Natalie Lorent ❤️

What about the other pathogens i hear you say? @alferes_de and @lifearc1 have you covered Rapid rRNA detection of H. influenzae, S. aureus, S. pneumoniae and M. catarrhalis in bronchiectasis sputum. Better than culture- the future of micro is molecular! publications.ersnet.org/content/erjor/…

Our latest paper just out in @LancetRespirMed 10 unanswered questions about DPP1 inhibition in bronchiectasis We outline key future clinical and research questions after the approval of the first new therapy for people with bronchiectasis. Congratulations Jiahui, Chloe and @MereteLong

In celebration of International Women’s Day, join us for the next #GAAPPAcademy webinar! 9 global experts share their journey with leadership and community impact as they discuss “The Role of Women in Patient Advocacy”. 🗓 9 March 2026 🕒 15:00 CET 🔗 Register: us06web.zoom.us/webinar/regist…

📣 A big step for patient-centred, evidence-based respiratory care. The #CAAT & #CERT tools — coordinated by Governance Boards at @gaapporg — are now included in the 2026 German National #COPD Guidelines 🇩🇪 🔗 lnkd.in/euG94-fj #RespiratoryHealth #PatientCare

New publication 📢 US survey (n=3,024) of adults with chronic conditions shows favorable attitudes toward flu/COVID vaccines & antivirals. Risk perception strongly linked to uptake. sciencedirect.com/science/articl… #Vaccines #PublicHealth #COPD #Asthma #diabetes @gaapporg @COPDKristen

Take the quiz to find out how well you understand #bronchiectasis

Brensocatib did not meet primary or secondary endpoints in the phase 2 BIRCH study in chronic rhinosinusitis without nasal polyps. Difficult/complex disease and interested to see the full data. Safety reassuring as with previous studies in bronchiectasis investor.insmed.com/2025-12-17-Ins…

Chronic Spontaneous Urticaria Study: Enrolling now. ✅ Reimbursement for travel ✅ No-cost study-related care from local doctors Click here to see if you qualify and if there is a study site near you in United States: embarqcsustudy.com Argentina: ar.embarqcsu.com Canada: ca.embarqcsu.com/en Chile: cl.embarqcsu.com Colombia: co.embarqcsu.com #EMBARQ-CSU

We are thrilled to announce that the Lung Health Resolution (part of the UN Political Declaration on NCDs and Mental Health) was adopted by the UN General Assembly! A near-unanimous vote secured this monumental declaration, which marks a significant step forward for the global respiratory community. Gaapp has been advocating relentlessly for the inclusion and passing of this resolution, and seeing this official adoption is a testament to the power of patient voices and global collaboration. What does this mean for patients? This declaration shifts the focus to action and commitment, setting concrete, measurable targets by 2030 that directly benefit people living with respiratory conditions: 🔹 Improved Access to Care Governments are tasked with ensuring at least 80% of primary health care facilities are stocked with essential medicines and basic technologies for NCDs, including lung diseases. 🔹 Reduced Financial Burden A target is set for at least 60% of countries to have measures in place to cover or limit the cost of essential NCD and mental health services. 🔹 Addressing Risk Factors The declaration explicitly calls for action on preventable risk factors like tobacco use and air pollution. This is a unique opportunity to improve the quality of life, access to treatment, and overall health outcomes for millions of patients worldwide. "This is a monumental moment for people living with lung conditions," says Tonya Winders, GAAPP President & CEO. "For too long, lung health has been under-recognized. This resolution validates that healthy lungs are essential to healthy lives." We're incredibly proud of the pivotal role patient advocates played in shaping this resolution. We appreciate everyone who joined us in asking for support for this resolution for over three years! ⚠️ While the global vote is a major win, the real work begins now: implementation at the country level. We urge all our partners, advocates, and policymakers to join us in supporting and driving the rapid adoption and execution of these ambitious, measurable targets into national health policies. Let's ensure these global commitments translate into tangible, positive changes for every patient in every nation. #UNGA #LungHealthResolution #LungHealth #NCDs #GlobalHealth #PatientAdvocacy #AdvocatedbyGAAPP

European Respiratory Review: A review focusing on hyperconcentrated mucus and the small airways in paediatric bronchiectasis bit.ly/4nsPWOe

New multi-country survey: Awareness of COPD among policymakers has risen from 37% (2022) → 59% (2025) 3 in 4+ now recognise COPD as a serious burden on health systems But awareness is not enough. Urgent action is needed to #SpeakUpForCOPD #COPD

7 days until we launch the 2025 COPD Baton Pass event! Join us in raising awareness of the importance of exercise to manage #COPD Join the "Inogen Step Challenge" group on StepUp, a fun step challenge app. join.thestepupapp.com/NllY2S

The tight relationship between #COPD and #CVD has never been well explained. CVD is not just a comorbidity but an intrinsic part of #COPD for many pts. Why? The answer is not what you think…

We're proud to share a new article co-authored by the GAAPP team and international partners, detailing Patient and Caregiver Perceptions on Education and Treatment Needs in Atopic Dermatitis (also known as eczema). Key finding: When considering new treatments, our survey participants prioritized information on safety and the mechanism of action (how it works) over potential side effects. ➡️ link.springer.com/article/10.100…

The GAAPP team is excited to announce we will be at the GOLD International Conference in Philadelphia, on 12–13 November 2025. We invite all healthcare professionals and stakeholders to stop by at our booth and attend our dedicated Learning Lab focused on enhancing shared decision-making and patient-physician communication in chronic respiratory care. This flexible session led by our experts Prof. Paul Jones, Stephanie Williams RRT, and Ruth Tal-Singer PhD will feature practical demonstrations and discussions on the application of three patient-centered tools in clinical practice and pulmonary rehabilitation: 🫁 COPD Exacerbation Recognition Tool (CERT) > See how this tool, developed to help people with COPD recognize and report exacerbations, can be integrated into patient education to prevent under-reporting and improve outcomes. Learn more: gaapp.org/cert 🫁 Chronic Airways Assessment Test (CAAT) > Understand how the CAAT allows for a meaningful conversation about health status in patients with conditions like COPD, asthma, and bronchiectasis. Learn more: gaapp.org/caat-cat 🫁 COPD Patient Care Map > Explore this innovative educational and advocacy tool that highlights patient and caregiver challenges across the entire COPD journey, from pre-diagnosis to long-term management. This is a fantastic opportunity to see how patient-reported and educational tools align with the latest 2025 GOLD treatment guidance to drive better, more patient-centered care. 📍 Location: 4th floor, near the exhibit hall. We look forward to connecting with you! #GOLDConference #COPD #SharedDecisionMaking #PulmonaryRehabilitation #PatientAdvocacy #RespiratoryHealth #CAAT #CERT #COPDCareMap

🎉 Excited to share my first publication in #AtopicDermatitis! 🌍 Our international survey explored how patients & caregivers view current education and treatment & where we can do better. Grateful to my amazing co-authors @gaapporg @COPDKristen link.springer.com/article/10.100…